Swiss healthcare group, two divisions, global reach
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
Swiss voters have rejected the Swiss People’s Party initiative to cap the country’s population at 10 million by 2050, with roughly 55% voting against and 45% in favour. The measure would have forced stricter asylum and family-reunification rules once population hit 9.5 million and could have ended free movement with the EU if the 10 million limit were breached.
A body of studies is showing that a blood marker called p-tau217 can forecast an elevated risk of cognitive impairment in healthy older adults years before symptoms appear. The evidence is not yet clinical-ready, but it is guiding trials that aim to slow or prevent Alzheimer’s disease and is being tested in Scotland’s primary care setting.
The FDA has approved daraxonrasib, sold as Rasonque by Revolution Medicines, for metastatic pancreatic cancer in patients who have received prior therapy or cannot take combination chemotherapy. A 500‑patient trial has shown median survival of 13.2 months versus 6.7 months on chemotherapy; a 30‑day supply will cost about $39,800.